| Target Price | $17.34 |
| Price | $9.80 |
| Potential |
76.94%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Aerovate Therapeutics Inc 2026 .
The average Aerovate Therapeutics Inc target price is $17.34.
This is
76.94%
register free of charge
$19.95
103.57%
register free of charge
$14.14
44.29%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend Aerovate Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aerovate Therapeutics Inc stock has an average upside potential 2026 of
76.94%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -85.27 | -3.58 |
| 15.06% | 95.80% | |
| P/E | negative |
7 Analysts have issued a Aerovate Therapeutics Inc forecast for earnings per share. The average Aerovate Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Aerovate Therapeutics Inc...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Oct 09 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 14 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Jun 16 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Oct 09 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 14 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Jun 16 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 07 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


